Skip to main content

Table 3 Distribution of PIFR

From: Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma

  Patients using 2 or more inhalers (%) Patients using 2 or more DPIs (%) PIFR0, L/min PIFRBT, L/min PIFRAT, L/min
All patients 61 (28.9) 27 (12.9) 118.0 (90.0,120.0) 55.4 ± 21.1 61.0 ± 18.8
Asthma/COPD group
 Asthma group 14 (15.1) 5 (5.4) 120.0 (90.0,120.0) 56.6 ± 20.6 62.9 ± 17.4
 COPD group 47 (40.2) 22 (18.8) 115.0 (85.0,120.0) 54.7 ± 21.5 60.0 ± 17.8
 P value (MD, 95%CI) / / 0.445 0.541 (MD = 1.9, 95% CI [−4.3, 8.1]) 0.278 ((MD = 3.2, 95% CI [−2.6, 8.9])
ND/FU group
ND group 10 (13.0) 5 (6.4) 105.0 (70.0, 120.0) 47.8 ± 18.0 55.9 ± 16.1
FU group 51 (38.3) 22 (16.6) 120.0 (95.0, 120.0) 60.0 ± 21.6 64.0 ± 17.9
p value / / 0.000 0.000 (MD = 12.1, 95%CI [6.2,18,1]) 0.002 (MD = 8.9, 95%CI [3.3,14.5])
AE/stable group
AE group 19 (54.3) 8 (22.9) 120.0 (90.0, 120.0) 51.3 ± 18.5 51.8 ± 11.4
Stable group 42 (24.1) 19 (10.9) 110.0 (77.5, 120.0) 56.5 ± 21.5 63.3 ± 17.9
p value / / 0.143 0.192 (MD = 5.2, 95% CI [−2.6,13.0]) 0.000 (MD = 13.0, 95% CI [−5.9, 20.1])
  1. Patients using 2 or more inhalers/DPIs are shown as number (%) patients. Data are shown as means ± standard deviation or median (25% quartile, 75%quartile). The PIFR data in Table 3 includes PIFR0 of all patients, and PIFRBT and PIFRAT only for patients using DPIs
  2. CI, confidence interval; COPD, chronic obstructive pulmonary disease; AE, acute exacerbation; ND, newly-diagnosed; FU, follow-up; PIFR0, peak inhalation flow rate measured at resistant of “pMDI”; PIFRBT, peak inhalation flow rate measured before-training; PIFRAT, peak inhalation flow rate measured after training; MD, mean difference